Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jon O. Curwen"'
Autor:
Sabina C. Cosulich, Jason S. Carroll, Robert McEwen, Igor Chernukhin, Mandy Lawson, Azadeh Cheraghchi-Bashi, Urszula M. Polanska, Anna D. Staniszewska, Larissa S. Carnevalli, Jon O. Curwen, Oona Delpuech, Rasmus Siersbaek, Claire Crafter, Chrysiis Michaloglou
Supplementary Figure S1. Vistusertib (AZD2014) causes a decrease in RB phosphorylation in the absence of cell cycle arrest. Supplementary Figure S2. Different mTOR inhibitors in combination with palbociclib cause a decrease in cell viability. Supplem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2971446864fbedb32439af08aab612
https://doi.org/10.1158/1535-7163.22510243
https://doi.org/10.1158/1535-7163.22510243
Autor:
Sabina C. Cosulich, Jason S. Carroll, Robert McEwen, Igor Chernukhin, Mandy Lawson, Azadeh Cheraghchi-Bashi, Urszula M. Polanska, Anna D. Staniszewska, Larissa S. Carnevalli, Jon O. Curwen, Oona Delpuech, Rasmus Siersbaek, Claire Crafter, Chrysiis Michaloglou
The cyclin dependent kinase (CDK)–retinoblastoma (RB)–E2F pathway plays a critical role in the control of cell cycle in estrogen receptor–positive (ER+) breast cancer. Small-molecule inhibitors of CDK4/6 have shown promise in this tumor type in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a430fac5fb19944258d4dc125065e6b
https://doi.org/10.1158/1535-7163.c.6539551.v1
https://doi.org/10.1158/1535-7163.c.6539551.v1
Autor:
Chris De Savi, Celina D'Cruz, Anne Marie Mazzola, Ermira Pazolli, Brendon Ladd, Graham Richmond, Claire Sadler, Steve Powell, Rachel Rowlinson, Zena Wilson, Graeme E. Walker, Gareth Davies, Michael Tonge, Stuart E. Pearson, Richard A. Norman, Thomas Moss, Philip MacFaul, Galith Karoutchi, Lyman J.L. Feron, Craig S. Donald, Michael Hulse, Peter Ballard, Camila de Almeida, Jon O. Curwen, Rowena J. Callis, David Buttar, Alfred A. Rabow, Mandy Lawson, Robert H. Bradbury, Hazel M. Weir
Legends for Supplementary Figures 1 - 7.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f2ea8b1988f522a97b4476bc1bfb489
https://doi.org/10.1158/0008-5472.22409537.v1
https://doi.org/10.1158/0008-5472.22409537.v1
Autor:
Chris De Savi, Celina D'Cruz, Anne Marie Mazzola, Ermira Pazolli, Brendon Ladd, Graham Richmond, Claire Sadler, Steve Powell, Rachel Rowlinson, Zena Wilson, Graeme E. Walker, Gareth Davies, Michael Tonge, Stuart E. Pearson, Richard A. Norman, Thomas Moss, Philip MacFaul, Galith Karoutchi, Lyman J.L. Feron, Craig S. Donald, Michael Hulse, Peter Ballard, Camila de Almeida, Jon O. Curwen, Rowena J. Callis, David Buttar, Alfred A. Rabow, Mandy Lawson, Robert H. Bradbury, Hazel M. Weir
Supplementary Figure 1 contains a Western blot showing the amount of estrogen receptor remaining after treatment of MCF-7 cells with AZD9496, fulvestrant and estradiol alongside GAPDH protein levels as an internal gel loading control; Supplementary F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c5919450d0037769dc8885c171e5d8
https://doi.org/10.1158/0008-5472.22409534.v1
https://doi.org/10.1158/0008-5472.22409534.v1
Autor:
Chris De Savi, Celina D'Cruz, Anne Marie Mazzola, Ermira Pazolli, Brendon Ladd, Graham Richmond, Claire Sadler, Steve Powell, Rachel Rowlinson, Zena Wilson, Graeme E. Walker, Gareth Davies, Michael Tonge, Stuart E. Pearson, Richard A. Norman, Thomas Moss, Philip MacFaul, Galith Karoutchi, Lyman J.L. Feron, Craig S. Donald, Michael Hulse, Peter Ballard, Camila de Almeida, Jon O. Curwen, Rowena J. Callis, David Buttar, Alfred A. Rabow, Mandy Lawson, Robert H. Bradbury, Hazel M. Weir
Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly intramuscular injection. Given its present limitations of dosing and route of administration, a more flexible orally available compound has been sou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121cf8596ca6963e592f8c1559e47fd8
https://doi.org/10.1158/0008-5472.c.6507809.v1
https://doi.org/10.1158/0008-5472.c.6507809.v1
Autor:
Chris De Savi, Celina D'Cruz, Anne Marie Mazzola, Ermira Pazolli, Brendon Ladd, Graham Richmond, Claire Sadler, Steve Powell, Rachel Rowlinson, Zena Wilson, Graeme E. Walker, Gareth Davies, Michael Tonge, Stuart E. Pearson, Richard A. Norman, Thomas Moss, Philip MacFaul, Galith Karoutchi, Lyman J.L. Feron, Craig S. Donald, Michael Hulse, Peter Ballard, Camila de Almeida, Jon O. Curwen, Rowena J. Callis, David Buttar, Alfred A. Rabow, Mandy Lawson, Robert H. Bradbury, Hazel M. Weir
Supplementary Table 1 contains crystallographic data collection and refinements statistics for AZD9496 binding to the human estrogen receptor α ligand binding domain, Supplementary Table 2 shows the rate constants for association, dissociation and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc4d27d54650a74388b4e3bbd209d6f
https://doi.org/10.1158/0008-5472.22409528
https://doi.org/10.1158/0008-5472.22409528
Autor:
Chris De Savi, Celina D'Cruz, Anne Marie Mazzola, Ermira Pazolli, Brendon Ladd, Graham Richmond, Claire Sadler, Steve Powell, Rachel Rowlinson, Zena Wilson, Graeme E. Walker, Gareth Davies, Michael Tonge, Stuart E. Pearson, Richard A. Norman, Thomas Moss, Philip MacFaul, Galith Karoutchi, Lyman J.L. Feron, Craig S. Donald, Michael Hulse, Peter Ballard, Camila de Almeida, Jon O. Curwen, Rowena J. Callis, David Buttar, Alfred A. Rabow, Mandy Lawson, Robert H. Bradbury, Hazel M. Weir
Methods are given for: the use of SILAC assays to measure the rate of estrogen receptor α peptide degradation over time, the measurement of compound binding affinity of estrogen receptor α ligand binding domain using BIAcore, immunoblotting of estr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500fb6b45ef15b3a4c16d2efaec374bf
https://doi.org/10.1158/0008-5472.22409531
https://doi.org/10.1158/0008-5472.22409531
Autor:
Chris, De Savi, Robert H, Bradbury, Alfred A, Rabow, Richard A, Norman, Camila, de Almeida, David M, Andrews, Peter, Ballard, David, Buttar, Rowena J, Callis, Gordon S, Currie, Jon O, Curwen, Chris D, Davies, Craig S, Donald, Lyman J L, Feron, Helen, Gingell, Steven C, Glossop, Barry R, Hayter, Syeed, Hussain, Galith, Karoutchi, Scott G, Lamont, Philip, MacFaul, Thomas A, Moss, Stuart E, Pearson, Michael, Tonge, Graeme E, Walker, Hazel M, Weir, Zena, Wilson
Publikováno v:
Journal of medicinal chemistry. 58(20)
The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahyd
Autor:
Stephen R, Wedge, Donald J, Ogilvie, Michael, Dukes, Jane, Kendrew, Rosemary, Chester, Janet A, Jackson, Sarah J, Boffey, Paula J, Valentine, Jon O, Curwen, Helen L, Musgrove, George A, Graham, Gareth D, Hughes, Andrew P, Thomas, Elaine S E, Stokes, Brenda, Curry, Graham H P, Richmond, Peter F, Wadsworth, Alison L, Bigley, Laurent F, Hennequin
Publikováno v:
Cancer research. 62(16)
ZD6474 [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine]is a potent, p.o. active, low molecular weight inhibitor of kinase insert domain-containing receptor [KDR/vascular endothelial growth factor receptor (
Autor:
Chris De Savi, Robert H. Bradbury, AlfredA. Rabow, Richard A. Norman, Camila de Almeida, David M. Andrews, Peter Ballard, David Buttar, Rowena J. Callis, Gordon S. Currie, Jon O. Curwen, Chris D. Davies, Craig S. Donald, Lyman J. L. Feron, Helen Gingell, Steven C. Glossop, Barry R. Hayter, Syeed Hussain, Galith Karoutchi, Scott G. Lamont
Publikováno v:
Journal of Medicinal Chemistry; Oct2015, Vol. 58 Issue 20, p8128-8140, 13p